33
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Up-Regulation of Imp3 Confers In Vivo Tumorigenicity on Murine Osteosarcoma Cells

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Osteosarcoma is a high-grade malignant bone tumor that manifests ingravescent clinical behavior. The intrinsic events that confer malignant properties on osteosarcoma cells have remained unclear, however. We previously established two lines of mouse osteosarcoma cells: AX cells, which are able to form tumors in syngeneic mice, and AXT cells, which were derived from such tumors and acquired an increased tumorigenic capacity during tumor development. We have now identified Igf2 mRNA-binding protein3 (Imp3) as a key molecule responsible for this increased tumorigenicity of AXT cells in vivo. Imp3 is consistently up-regulated in tumors formed by AX cells, and its expression in these cells was found to confer malignant properties such as anchorage-independent growth, loss of contact inhibition, and escape from anoikis in vitro. The expression level of Imp3 also appeared directly related to tumorigenic ability in vivo which is the critical determination for tumor-initiating cells. The effect of Imp3 on tumorigenicity of osteosarcoma cells did not appear to be mediated through Igf2-dependent mechanism. Our results implicate Imp3 as a key regulator of stem-like tumorigenic characteristics in osteosarcoma cells and as a potential therapeutic target for this malignancy.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: found

          Targeting mitochondrial glutaminase activity inhibits oncogenic transformation.

          Rho GTPases impact a number of activities important for oncogenesis. We describe a small molecule inhibitor that blocks oncogenic transformation induced by various Rho GTPases in fibroblasts, and the growth of human breast cancer and B lymphoma cells, without affecting normal cells. We identify the target of this inhibitor to be the metabolic enzyme glutaminase, which catalyzes the hydrolysis of glutamine to glutamate. We show that transformed fibroblasts and breast cancer cells exhibit elevated glutaminase activity that is dependent on Rho GTPases and NF-κB activity, and is blocked by the small molecule inhibitor. These findings highlight a previously unappreciated connection between Rho GTPase activation and cellular metabolism and demonstrate that targeting glutaminase activity can inhibit oncogenic transformation. Copyright © 2010 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Anoikis resistance and tumor metastasis.

            As a barrier to metastases, cells normally undergo apoptosis after they lose contact with their extra cellular matrix or their neighbouring cells. This cell death process has been termed "anoikis". Tumour cells that acquire malignant potential have developed mechanisms to resist anoikis and thereby survive after detachment from their primary site and while travelling through the lymphatic and circulatory systems. Defects in the death receptor pathway of caspase activation, such as the over-expression of the caspase-8 inhibitor FLIP, can render cells resistant to anoikis. Likewise, roadblocks in the mitochondrial pathway, such as over-expression of the Bcl-2 family of anti-apoptotic proteins, can also confer resistance to anoikis. This review will focus on the roles of the death receptor and mitochondrial pathways in anoikis and anoikis resistance and how targeting defects in these pathways can restore sensitivity to anoikis and serve as the basis for therapeutic adjuncts that prevent metastasis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Aberrant epigenetic landscape in cancer: how cellular identity goes awry.

              Appropriate patterns of DNA methylation and histone modifications are required to assure cell identity, and their deregulation can contribute to human diseases, such as cancer. Our aim here is to provide an overview of how epigenetic factors, including genomic DNA methylation, histone modifications, and microRNA regulation, contribute to normal development, paying special attention to their role in regulating tissue-specific genes. In addition, we summarize how these epigenetic patterns go awry during human cancer development. The possibility of "resetting" the abnormal cancer epigenome by applying pharmacological or genetic strategies is also discussed. Copyright © 2010 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, USA )
                1932-6203
                2012
                30 November 2012
                : 7
                : 11
                : e50621
                Affiliations
                [1 ]Division of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan
                [2 ]Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan
                [3 ]Department of Pathophysiology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Tokyo, Japan
                [4 ]Department of Orthopedic Surgery, School of Medicine, Keio University, Tokyo, Japan
                [5 ]Kasai R&D Center, Daiichi Sankyo Co. Ltd., Tokyo, Japan
                [6 ]Department of Molecular Biology, School of Medicine, Keio University, Tokyo, Japan
                [7 ]Japan Science and Technology Agency, Core Research for Evolutional Science and Technology (CREST), Tokyo, Japan
                National Cancer Center Research Institute, Japan
                Author notes

                Competing Interests: Tomoki Ishikawa is employed by a commercial company Kasai R&D Center, Daiichi Sankyo Co. Ltd., Tokyo, Japan. He is a researcher at Biological Research Laboratories IV at Kasai R&D Center, Daiichi Sankyo Co. Ltd and joins to this study as a Research Student, Graduate School of Medicine, Keio University. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

                Conceived and designed the experiments: AU TS TI ES NO K. Miyoshi HS. Performed the experiments: AU TS K. Masuda SIY TI KMi. Analyzed the data: AU TS K. Miyoshi HS. Contributed reagents/materials/analysis tools: TI ES NO SK AM YT KB DA HS. Wrote the paper: AU TS HS.

                Article
                PONE-D-12-26145
                10.1371/journal.pone.0050621
                3511546
                23226335
                feafa619-8fb0-4a61-90c1-a5c5b61460fd
                Copyright @ 2012

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 28 August 2012
                : 22 October 2012
                Page count
                Pages: 11
                Funding
                This work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and CREST, JST, Japan (TS #2401320) http://kaken.nii.ac.jp/d/r/40407101.en.html, (HS #22130007) http://www.cancer-stem-cell.com/, CREST: http://www.jst.go.jp/kisoken/crest/en/research_area/ongoing/area03-1.html. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Biology
                Model Organisms
                Animal Models
                Mouse
                Molecular Cell Biology
                Medicine
                Clinical Research Design
                Animal Models of Disease
                Oncology
                Basic Cancer Research
                Tumor Physiology
                Cancers and Neoplasms
                Bone and Soft Tissue Sarcomas
                Osteosarcoma
                Pediatrics
                Pediatric Oncology

                Uncategorized
                Uncategorized

                Comments

                Comment on this article